PIA
MRSN

Piedmont Investment Advisors’s Mersana Therapeutics MRSN Stock Holding History

Piedmont Investment Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9
Closed -$4K – 1792
2018
Q2 		$4K Buy
+9
New +$3.95K ﹤0.01% 2248

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Piedmont Investment Advisors's MRSN Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Mersana Therapeutics (MRSN) in Q3 2018, closing a stake of 9 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in MRSN in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 46 funds tracked by Wall St. Rank hold MRSN as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Mersana Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 9 Mersana Therapeutics shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Mersana Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Mersana Therapeutics position peaked at $4K in Q2 2018.
  • 46 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.